[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 41 of about 41
38. Griffin D, Manuck TA, Hoffman MS: Adenocarcinoma in situ of the cervix in pregnancy. Gynecol Oncol; 2005 May;97(2):662-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ of the cervix in pregnancy.
  • INTRODUCTION: The number of patients diagnosed with adenocarcinoma in situ of the cervix has increased in the last decade.
  • CASES: In this report, we describe three patients diagnosed with adenocarcinoma in situ of the cervix during pregnancy.
  • DISCUSSION: The management of adenocarcinoma in situ of the cervix may include procedures which present substantial risks to an ongoing pregnancy and more conservative management may be warranted in many instances.
  • [MeSH-major] Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Adult. Carcinoma in Situ / diagnosis. Carcinoma in Situ / surgery. Female. Humans. Pregnancy


39. Sharpless KE, Schnatz PF, Mandavilli S, Greene JF, Sorosky JI: Dysplasia associated with atypical glandular cells on cervical cytology. Obstet Gynecol; 2005 Mar;105(3):494-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysplasia associated with atypical glandular cells on cervical cytology.
  • Most women aged younger than 35 years had a squamous abnormality, whereas women aged 35 years or older had a greater diversity of squamous and glandular lesions and accounted for all cases of endometrial cancer, adenocarcinoma in situ, and cervical adenocarcinoma.
  • [MeSH-major] Cervix Uteri / pathology. Uterine Cervical Dysplasia / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / pathology. Female. Humans. Middle Aged. Uterine Cervical Neoplasms / pathology. Vaginal Smears


40. Zafar N, Balazs L, Benstein BD: Synchronous high-grade squamous intraepithelial lesion and adenocarcinoma in situ of cervix in a young woman presenting with hyperchromatic crowded groups in the cervical cytology specimen: report of a case. Diagn Cytopathol; 2008 Nov;36(11):823-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous high-grade squamous intraepithelial lesion and adenocarcinoma in situ of cervix in a young woman presenting with hyperchromatic crowded groups in the cervical cytology specimen: report of a case.
  • We report a 29-year-old woman who underwent routine gynecologic evaluation at a community clinic and had a cervical sample drawn for liquid-based cytologic evaluation.
  • At biopsy, the cervix contained synchronous squamous cell carcinoma in situ, secondarily involving endocervical glands, and neighboring adenocarcinoma in situ.
  • This case re-emphasizes the challenge associated with accurate evaluation of HCG at cytology, the significance of ancillary testing for surrogate markers of high-risk HPV (HR-HPV) infection, the need for adjunct testing for HPV-DNA in the setting of HCG at cervical cytology, and a recommendation to set up studies to evaluate the role of surrogate markers of HR-HPV infection in cytologic samples with HCG.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. Uterine Cervical Neoplasms / pathology


41. FUTURE II Study Group: Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis; 2007 Nov 15;196(10):1438-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV) L1 virus-like-particle (VLP) vaccine has been shown to be 95%-100% effective in preventing cervical and genital disease related to HPV-6, -11, -16, and -18 in 16-26-year-old women naive for HPV vaccine types.
  • RESULTS: Vaccination was 100% effective (95% confidence interval [CI], 79%-100%) in preventing incident cervical intraepithelial neoplasia 2 or 3 or cervical adenocarcinoma in situ caused by the HPV type or types for which the women were negative at enrollment.
  • [MeSH-minor] Adolescent. Adult. Antibodies, Viral / blood. Cervical Intraepithelial Neoplasia / prevention & control. Cervical Intraepithelial Neoplasia / virology. DNA, Viral / analysis. Double-Blind Method. Enzyme-Linked Immunosorbent Assay. Female. Humans. Injections, Intramuscular. Polymerase Chain Reaction. Prospective Studies. Treatment Outcome. Uterine Cervical Neoplasms / prevention & control. Uterine Cervical Neoplasms / virology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Infect Dis. 2007 Nov 15;196(10):1431-2 [18008218.001]
  • (PMID = 18008221.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / DNA, Viral; 0 / Papillomavirus Vaccines
  •  go-up   go-down






Advertisement